Moderna
Moderna's revenue fell 39.9% to $1.9 billion in fiscal 2025. Its operating margin was −158.1%, down from −121.9% a year earlier. Free cash flow was −$2.1 billion. It paid out $2 million in dividends and buybacks. The diluted share count rose 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Moderna does
Moderna develops medicines and vaccines built on messenger RNA (mRNA), the molecule that carries instructions from genes to a cell's protein-making machinery. It has three commercial products: Spikevax and mNEXSPIKE, its COVID vaccines, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). It launched mNEXSPIKE in the third quarter of 2025 and says it is now its top product in the U.S. retail channel.
Moderna earns its revenue from selling these vaccines. Total revenue in 2025 was $1.9 billion, largely from COVID vaccines. It also has experimental medicines in development for cancer, rare diseases and infectious diseases. With Merck, it is testing an individualized cancer therapy called intismeran in eight Phase 2 and Phase 3 trials. It has applications under review for a flu vaccine and a combined flu and COVID vaccine, and a norovirus vaccine in a Phase 3 study. In January 2026 it agreed with Recordati to carry a rare disease therapy through the final stages of development and, if approved, sell it worldwide.
Moderna says it has built a global manufacturing network since 2022, including facilities in the UK, Canada and Australia. It says the vaccine and drug markets are intensely competitive.
Its biggest risks, as it describes them
- Regulatory and market uncertainty that has affected, and may keep affecting, demand for its products.
- Difficulty carrying out its near-term strategy and focused pipeline of medicines.
- Intense competition in vaccines and drugs, and commercial challenges it has already faced.
- Delays or failures in clinical trials and in getting regulatory approvals for new products.
- Dependence on third-party reimbursement, and on single-source suppliers and manufacturing.
Income statement
From fiscal 2021 to 2022, earnings per share fell 28.9% a year and net income 31.5% a year, while buybacks cut the share count by 3%. Moderna then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 10,727 | 9,902 | 8,604 | 7,025 | 5,799 |
| Debt incl. finance leases | — | — | — | 62 | 635 |
| Net debt (negative means net cash) | — | — | — | −6,963 | −5,164 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.0x | 0.1x |
| Interest coverage | 949.7x | 376.8x | −108.7x | −164.4x | −307.4x |
| Current ratio | 1.8x | 2.7x | 3.4x | 3.7x | 3.3x |
| Quick ratio | 1.6x | 2.5x | 3.4x | 3.6x | 3.2x |
Cash flow
Projections
Project Moderna's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Moderna says to expect
- Full year 2026: revenue growth
The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth.
- Full year 2026: cost of sales
Cost of sales for 2026 is expected to be approximately $1.7 billion, including the previously announced $0.9 billion non-recurring litigation settlement charge.
- Full year 2026: research and development expenses
Research and development expenses for 2026 are expected to be approximately $2.7 billion, reduced from the Company's previous expectation of approximately $2.9 billion.
- Full year 2026: selling, general and administrative expenses
Selling, general and administrative expenses for 2026 are expected to be approximately $1.0 billion, unchanged from previous forecast.
- Year-end 2026: cash and investments
The Company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Moderna shares on the open market, and 6 insiders sold $98.5 million, $97.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Stephen HogePresident | Sold plan | 39,215 | $211.61 | $8.3 million | Form 4 |
| Nov 16, 2026 | Stephen HogePresident | Sold plan | 39,160 | $219.66 | $8.6 million | Form 4 |
| Oct 15, 2026 | Stephen HogePresident | Sold plan | 39,145 | $220.72 | $8.6 million | Form 4 |
| Oct 14, 2026 | Stephen HogePresident | Sold plan | 39,224 | $213.48 | $8.4 million | Form 4 |
| Sep 15, 2026 | Stephen HogePresident | Sold plan | 40,281 | $146.07 | $5.9 million | Form 4 |
| Sep 14, 2026 | Stephen HogePresident | Sold plan | 40,294 | $144.13 | $5.8 million | Form 4 |
| Sep 10, 2026 | James M MockChief Financial Officer | Sold plan | 34,836 | $134.49 | $4.7 million | Form 4 |
| Sep 1, 2026 | Shannon Thyme KlingerChief Legal Officer | Sold plan | 3,471 | $139.95 | $485,766 | Form 4 |
| Aug 5, 2026 | Stephane BancelChief Executive Officer, Director | Sold plan | 499,246 | $57.52 | $28.7 million | Form 4 |
| Jul 15, 2026 | Stephen HogePresident | Sold plan | 53,336 | $67.60 | $3.6 million | Form 4 |
| Jun 15, 2026 | Stephen HogePresident | Sold plan | 53,336 | $51.37 | $2.7 million | Form 4 |
| Jun 4, 2026 | Shannon Thyme KlingerChief Legal Officer | Sold plan | 3,471 | $50.00 | $173,550 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 2 of 9 |
| Rule of 40 | −120.3% | −178.1% | −146.2% |
| Altman Z'' | 6.65 | 6.71 | 5.12 |
| Accruals ratio | −7.2% | −3.4% | −7.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | 2 of 9 |
Compare
Put Moderna side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Moderna | FY25 | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 | |
| Pfizer | FY25 | −1.6% | — | 14.5% | 7.2% | 3.2x | 6 | Compare |
| Johnson & Johnson | FY25 | 6.0% | — | 20.9% | 28.6% | 0.7x | 4 | Compare |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 108 | 206 | 135 | 60 | 803 | 18,471 | 19,263 | 6,848 | 3,236 | 1,944 |
| Revenue growth | — | 89.9% | −34.4% | −55.6% | 1,238.3% | 2,200.2% | 4.3% | −64.5% | −52.8% | −39.9% |
| Gross profit | — | — | 135 | 60 | 795 | 15,854 | 13,847 | 2,155 | 1,772 | 1,076 |
| Research and development | 275 | 410 | 454 | 496 | 1,370 | 1,991 | 3,295 | 4,845 | 4,543 | 3,132 |
| Operating income | −224 | −269 | −413 | −546 | −763 | 13,296 | 9,420 | −4,239 | −3,945 | −3,074 |
| Net income | −216 | −256 | −385 | −514 | −747 | 12,202 | 8,362 | −4,714 | −3,561 | −2,822 |
| Diluted EPS (US$) | −3.79 | −4.18 | −4.95 | −1.55 | −1.96 | 28.29 | 20.12 | −12.33 | −9.28 | −7.26 |
| Diluted shares (millions) | 61 | 64 | 81 | 331 | 381 | 431 | 416 | 382 | 384 | 389 |
| Cash flow | ||||||||||
| Cash from operations | 67 | −332 | −331 | −459 | 2,027 | 13,620 | 4,981 | −3,118 | −3,004 | −1,873 |
| Capital expenditure | 33 | 58 | 106 | 32 | 68 | 284 | 400 | 707 | 1,051 | 192 |
| Free cash flow | 34 | −390 | −437 | −491 | 1,959 | 13,336 | 4,581 | −3,825 | −4,055 | −2,065 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 857 | 3,329 | 1,153 | 0 | 2 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85 | 0 | 0 |
| Stock-based compensation | 39 | 40 | 73 | 81 | 93 | 142 | 226 | 305 | 429 | 483 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 50 | 756 | 1,521 | 1,103 | 4,608 | 10,727 | 9,902 | 8,604 | 7,025 | 5,799 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 62 | 635 |
| Total assets | — | 1,084 | 1,962 | 1,589 | 7,337 | 24,669 | 25,858 | 18,426 | 14,142 | 12,338 |
| Total liabilities | — | 459 | 432 | 415 | 4,776 | 10,524 | 6,735 | 4,572 | 3,241 | 3,688 |
| Shareholders' equity | −335 | −551 | 1,530 | 1,175 | 2,561 | 14,145 | 19,123 | 13,854 | 10,901 | 8,650 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 100.0% | 100.0% | 99.0% | 85.8% | 71.9% | 31.5% | 54.8% | 55.4% |
| Operating margin | −206.4% | −130.9% | −306.0% | −910.0% | −95.0% | 72.0% | 48.9% | −61.9% | −121.9% | −158.1% |
| Net margin | −199.5% | −124.3% | −284.8% | −856.7% | −93.0% | 66.1% | 43.4% | −68.8% | −110.0% | −145.2% |
| Free cash flow margin | 31.0% | −189.4% | −323.3% | −818.3% | 244.0% | 72.2% | 23.8% | −55.9% | −125.3% | −106.2% |
| Rule of 40 (growth + FCF margin) | — | −99.5% | −357.6% | −873.9% | 1,482.3% | 2,272.4% | 28.1% | −120.3% | −178.1% | −146.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | −65.4% |
| Return on equity | — | — | −78.6% | −38.0% | −40.0% | 146.1% | 50.3% | −28.6% | −28.8% | −28.9% |
| Return on assets | — | — | −25.3% | −28.9% | −16.7% | 76.2% | 33.1% | −21.3% | −21.9% | −21.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |